Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas

被引:44
作者
Kakehi, Y
Özdemir, E
Habuchi, T
Yamabe, H
Hashimura, H
Katsura, Y
Yoshida, O
机构
[1] Kyoto Univ, Fac Med, Dept Urol, Sakyo Ku, Kyoto 60601, Japan
[2] Kyoto Univ Hosp, Anat Pathol Lab, Sakyo Ku, Kyoto 60601, Japan
[3] Natl Himeji Hosp, Dept Urol, Himeji, Hyogo 670, Japan
[4] Natl Himeji Hosp, Dept Pathol, Himeji, Hyogo 670, Japan
来源
JAPANESE JOURNAL OF CANCER RESEARCH | 1998年 / 89卷 / 02期
关键词
urothelial cancer; chemosensitivity; p53; mdm2;
D O I
10.1111/j.1349-7006.1998.tb00551.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It has been controversial whether cancer cells harboring loss or inactivation of the tumor suppressor p53 are resistant or sensitive to DNA-damaging agents including cisplatin and doxorubicin. Overexpression of mdm2 oncoprotein, a negative regulator of p53, is assumed to be an alternative to p53 dysfunction. Archival urothelial carcinoma specimens obtained from 60 patients prior to cisplatin-based chemotherapy were immunohistochemically studied for overexpression of p53 and mdm2. Thirty-two patients (group I) were treated with chemotherapy in the neoadjuvant setting, while 28 patients (group II) underwent chemotherapy for distant metastases or inoperable locoregional tumors. In group I, the responsiveness was correlated with staining status of p53 (P=0.0225) and the combination of p53 and mdm2 (P=0.0497). Negative staining of p53 and negative for both p53 and mdm2 could have predicted favorable response to chemotherapy in 16 of 18 (88.9%) and in 12 of 13 (92.3%) tumors, respectively, On the other hand, p53-positive and p53 and/or mdm2-positive staining could have predicted poor response only in 7 of 14 (50.0%) and 8 of 19 (42.1%) tumors, respectively, Disease-specific survival of the p53-negative group was significantly superior to that of the p53-positive group (P=0.0086), Difference in survival did not become more significant when overexpression of mdm2 was taken into consideration (P=0.0456), In contrast, in group II, there was no correlation of responsiveness to chemotherapy or survival with p53- or p53/mdm2-staining status. The patients with urothelial carcinomas negative for overexpression of p53 will benefit from neoadjuvant chemotherapy, From clinical viewpoint, however, p53 status alone or the combination of p53 and mdm2 status is not enough to identify those patients who will not benefit from the treatment.
引用
收藏
页码:214 / 220
页数:7
相关论文
共 31 条
[21]   P53 STATUS AND THE EFFICACY OF CANCER-THERAPY IN-VIVO [J].
LOWE, SW ;
BODIS, S ;
MCCLATCHEY, A ;
REMINGTON, L ;
RULEY, HE ;
FISHER, DE ;
HOUSMAN, DE ;
JACKS, T .
SCIENCE, 1994, 266 (5186) :807-810
[22]   P53-DEPENDENT APOPTOSIS MODULATES THE CYTOTOXICITY OF ANTICANCER AGENTS [J].
LOWE, SW ;
RULEY, HE ;
JACKS, T ;
HOUSMAN, DE .
CELL, 1993, 74 (06) :957-967
[23]  
MAESTRO R, 1992, ONCOGENE, V7, P1159
[24]   THE MDM-2 ONCOGENE PRODUCT FORMS A COMPLEX WITH THE P53 PROTEIN AND INHIBITS P53-MEDIATED TRANSACTIVATION [J].
MOMAND, J ;
ZAMBETTI, GP ;
OLSON, DC ;
GEORGE, D ;
LEVINE, AJ .
CELL, 1992, 69 (07) :1237-1245
[25]   Strong correlation of basement membrane degradation with p53 inactivation and/or mdm2 overexpression in superficial urothelial carcinomas [J].
Ozdemir, E ;
Kakehi, Y ;
Okuno, H ;
Habuchi, T ;
Okada, Y ;
Yoshida, O .
JOURNAL OF UROLOGY, 1997, 158 (01) :206-211
[26]  
RUSCH V, 1995, CANCER RES, V55, P5038
[27]   PROGNOSTIC VALUE OF P53 NUCLEAR OVEREXPRESSION IN PATIENTS WITH INVASIVE BLADDER-CANCER TREATED WITH NEOADJUVANT MVAC [J].
SARKIS, AS ;
BAJORIN, DF ;
REUTER, VE ;
HERR, HW ;
NETTO, G ;
ZHANG, ZF ;
SCHULTZ, PK ;
CORDONCARDO, C ;
SCHER, HI .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (06) :1384-1390
[28]   The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry [J].
Sjogren, S ;
Inganas, M ;
Norberg, T ;
Lindgren, A ;
Nordgren, H ;
Holmberg, L ;
Bergh, J .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (3-4) :173-182
[29]   INTERACTION OF THE P53-REGULATED PROTEIN GADD45 WITH PROLIFERATING CELL NUCLEAR ANTIGEN [J].
SMITH, ML ;
CHEN, IT ;
ZHAN, QM ;
BAE, IS ;
CHEN, CY ;
GILMER, TM ;
KASTAN, MB ;
OCONNOR, PM ;
FORNACE, AJ .
SCIENCE, 1994, 266 (5189) :1376-1380
[30]   M-VAC (METHOTREXATE, VINBLASTINE, DOXORUBICIN AND CISPLATIN) FOR ADVANCED TRANSITIONAL CELL-CARCINOMA OF THE UROTHELIUM [J].
STERNBERG, CN ;
YAGODA, A ;
SCHER, HI ;
WATSON, RC ;
HERR, HW ;
MORSE, MJ ;
SOGANI, PC ;
VAUGHAN, ED ;
BANDER, N ;
WEISELBERG, LR ;
GELLER, N ;
HOLLANDER, PS ;
LIPPERMAN, R ;
FAIR, WR ;
WHITMORE, WF .
JOURNAL OF UROLOGY, 1988, 139 (03) :461-469